The body of evidence supporting measurable residual disease (MRD) assessment in routine patient care is growing. Leading experts share their views on MRD, the evolving role of MRD testing in lymphoid cancers, and insights on incorporating clonoSEQ (Adaptive Biotechnologies) into clinical practice decisions to assess MRD.

Read article.

Posted on 5/14/2021